Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280825 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von João Paulo Portela Catani und 5 weiteren Autor:innen. Beteiligte Einrichtung: VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium. Hauptthemen laut MEDLINE: Cross Protection, Immune Sera, Influenza B virus, Influenza, Human. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
- Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
- Gnomixx, Melle, Belgium.
- Sanofi, Research North America, Cambridge, Massachusetts, United States of America.
ORCID-Profile: João Paulo Portela Catani, Tine Ysenbaert, Thorsten U Vogel, Xavier Saelens
Förderung
- Sanofi
Zitieren
APA
Portela Catani, J. P., Ysenbaert, T., Smet, A., Vuylsteke, M., Vogel, T. U., & Saelens, X. (2023). Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B. PLOS ONE. https://doi.org/10.1371/journal.pone.0280825
Vancouver
Portela Catani JP, Ysenbaert T, Smet A, Vuylsteke M, Vogel TU, Saelens X. Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B. PLOS ONE. 2023. doi:10.1371/journal.pone.0280825
BibTeX
@article{PortelaCatani2023,
author = {Portela Catani, João Paulo and Ysenbaert, Tine and Smet, Anouk and Vuylsteke, Marnik and Vogel, Thorsten U and Saelens, Xavier},
title = {Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280825}
}
EUVIMED